Search Results
John Kuruvilla | EHA 18 | SADAL clinical trial in DLBCL
Lymphoma Treatment Options John Kuruvilla
T Cell Engager Antibodies – focus on Hematological Malignancies | Presented by Dr. John Kuruvilla
Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma
Phase 2 Trial of Selinexor Shows Durable Responses in DLBCL
CARE Update in Hodgkin's Lymphoma by Dr. John Kuruvilla (Princess Margaret Cancer Centre)
Response Data from the JULIET Trial in DLBCL
CCH-QC Montréal 2017: Dr. John Kuruvilla - Early Treatment in Follicular Lymphoma
Tafasitamab for R/R DLBCL
Dr. Kuruvilla on the Broad Utility of Pembrolizumab in Hodgkin Lymphoma
Pembrolizumab Improves PFS in Hodgkin Lymphoma Compared With Brentuximab Vedotin
Phase III KEYNOTE-204: does prior therapy impact outcomes in R/R cHL?
